Dark Forest Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Dark Forest Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-33,397	Closed	-$163K	–	1300
2025 Q3	$163K	Buy	+33,397	New	+$175K	0.01%	1092
2023 Q4	–	Sell	-17,561	Closed	-$134K	–	985
2023 Q3	$134K	Sell	17,561 -27,733	-61%	-$277K	0.01%	1044
2023 Q2	$338K	Sell	45,294 -6,973	-13%	-$48.8K	0.03%	779
2023 Q1	$349K	Buy	52,267 +51,584	+7,553%	+$409K	0.08%	230
2022 Q4	$5.27K	Buy	+683	New	+$6.7K	﹤0.01%	855
2022 Q3	–	Sell	-841	Closed	-$7K	–	1400
2022 Q2	$7K	Buy	+841	New	+$5.63K	﹤0.01%	590

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Dark Forest Capital Management's RXRX Position: Q4 2025 in Review

Dark Forest Capital Management sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 33,397 shares — an estimated $163K sold.

Dark Forest Capital Management first reported a position in RXRX in Q2 2022 and held it in 6 quarters. The position peaked at $349K in Q1 2023. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

Dark Forest Capital Management reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Dark Forest Capital Management sold 33,397 Recursion Pharmaceuticals shares in Q4 2025, an estimated $163K.
Dark Forest Capital Management first reported a position in Recursion Pharmaceuticals in Q2 2022 and held it in 6 quarters.
Dark Forest Capital Management's Recursion Pharmaceuticals position peaked at $349K in Q1 2023.
333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Dark Forest Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.